24 April 2018 I Report and related presentation materials are available here.
26 Feb 2018 I Orion's Financial Statement documents for 2017 are published, and include Financial Statements, the report of the Board of Directors and the Auditor's report.
|4/24/2018||Orion Group Interim Report January-March 2018|
|4/21/2018||Orion to sell its Orion Diagnostica division - Due to the transaction Orion updates its outlook|
|3/20/2018||Orion Corporation: Organising meeting of the Board of Directors|
|3/20/2018||Orion Corporation: Decisions by the AGM on 20 March 2018|
|4/30/2018||Orion has completed the sale of Orion Diagnostica business division|
|4/10/2018||Publishing of Orion Corporation's Interim Report for January-March 2018 on 24 April 2018|
|4/3/2018||Status update of the Phase III ARAMIS clinical trial with darolutamide in patients with non-metastatic castration-resistant prostate cancer|
|3/19/2018||Orion has received positive conclusions for the salmeterol-fluticasone Easyhaler® combination under the EU's decentralized procedures|
The product and service portfolio of Orion includes a variety of human pharmaceuticals, veterinary drugs, APIs, contract manufacturing and diagnostic tests.
Orion’s pharmaceutical innovations are created within its R&D organisation. The organisation employs top professionals in the field of drug molecule development and optimisation.
One key area of Orion's business is Critical Care. Our portfolio includes Simdax® for acute heart failure and Precedex® and Dexdor® for sedation. Read more about Orion's proprietary products and other human pharmaceuticals.